David Weingeist
Director, Leader - Scientific & Oncology Diagnostics Johnson & Johnson
David is the Global Dx Development Leader for the Bladder Cancer Team at Johnson & Johnson Innovative Medicine, where he is responsible for development of global diagnostic solutions in support of the bladder cancer precision medicine portfolio.
David received a bachelor’s degree in Chemical Engineering from Washington University in St. Louis and a master’s degree in BioScience Enterprise from Cambridge University. He earned his doctorate in Bioengineering from the Massachusetts Institute of Technology, where he conducted his graduate research developing a novel assay to measure DNA damage and repair kinetics. His professional experience prior to Johnson & Johnson Innovative Medicine includes seven years in life science strategy consulting with a focus in precision medicine and another five years at Roche Pharmaceuticals (Genentech and Foundation Medicine) in the personalized healthcare, global product strategy organization.
Seminars
- Urine-based LBx for patient selection in bladder cancer
- Implementation of urine-based LBx in clinical practice as a non-invasive testing option
- Future applications of urine-based LBx, including MRD and patient monitoring
